[Skip to Content]
[Skip to Content Landing]
Sept 11, 1967

The Risk of Bacterial Endocarditis During Antirheumatic Prophylaxis

Author Affiliations

From the departments of pediatrics (Dr. Doyle) and medicine (Drs. Spagnuolo and Taranta); New York University School of Medicine and New York University Medical Center; Irvington House Institute (Drs. Spagnuolo and Taranta); Sinai Hospital of Baltimore (Drs. Kuttner and Markowitz); and the Children's Medical and Surgical Center, Johns Hopkins Hospital, Baltimore (Drs. Kuttner and Markowitz).

JAMA. 1967;201(11):807-812. doi:10.1001/jama.1967.03130110033008

This study was undertaken to determine whether continuous antirheumatic prophylaxis increased the risk of bacterial endocarditis (BE) or of its resistance to therapy. Sixteen episodes of BE occurred among children and adolescents with rheumatic heart disease who had been treated prophylactically for 3,615 patient years, a rate of 4.4 episodes per 1,000 patient years. This rate is similar to that observed in the preprophylactic era. The onset of BE in these patients often simulated a recurrence of rheumatic fever because of the frequent joint manifestations. Therefore, blood cultures are indicated whenever a patient with rheumatic heart disease has joint symptoms. Eight of the 16 organisms isolated were sensitive to penicillin in vitro; four were slightly sensitive; and four were resistant. The resistance was not of sufficient magnitude to interfere with a satisfactory therapeutic response. These data suggest no increased risk of BE in patients being treated prophylactically.